wikidoc - Recent changes [en]

Sandbox

2026-04-28T01:40:03Z

← Older revision		Revision as of 01:40, 28 April 2026
Line 30:		Line 30:
	* [[Statin\|Statins]]: high-intensity statin therapy for atherosclerotic TAA		* [[Statin\|Statins]]: high-intensity statin therapy for atherosclerotic TAA

	== 2022 ACC/AHA Guidelines for the Diagnosis and Management of Aortic Disease <ref name="pmid36334952">{{cite journal \|vauthors=Isselbacher EM, Preventza O, Hamilton Black Iii J, Augoustides JG, Beck AW, Bolen MA, Braverman AC, Bray BE, Brown-Zimmerman MM, Chen EP, Collins TJ, DeAnda A, Fanola CL, Girardi LN, Hicks CW, Hui DS, Jones WS, Kalahasti V, Kim KM, Milewicz DM, Oderich GS, Ogbechie L, Promes SB, Ross EG, Schermerhorn ML, Times SS, Tseng EE, Wang GJ, Woo YJ \|title=2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines \|journal=J Am Coll Cardiol \|volume=80 \|issue=24 \|pages=e223–e393 \|date=December 2022 \|pmid=36334952 \|pmc=9860464 \|doi=10.1016/j.jacc.2022.08.004 \|url=}}</ref> <ref name="url2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines \| JACC">{{cite web \|url=https://www.jacc.org/doi/10.1016/j.jacc.2022.08.004 \|title=2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines \| JACC \|format= \|work= \|accessdate=}}</ref> ==		==2022 ACC/AHA Guidelines for the Diagnosis and Management of Aortic Disease <ref name="pmid36334952">{{cite journal \|vauthors=Isselbacher EM, Preventza O, Hamilton Black Iii J, Augoustides JG, Beck AW, Bolen MA, Braverman AC, Bray BE, Brown-Zimmerman MM, Chen EP, Collins TJ, DeAnda A, Fanola CL, Girardi LN, Hicks CW, Hui DS, Jones WS, Kalahasti V, Kim KM, Milewicz DM, Oderich GS, Ogbechie L, Promes SB, Ross EG, Schermerhorn ML, Times SS, Tseng EE, Wang GJ, Woo YJ \|title=2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines \|journal=J Am Coll Cardiol \|volume=80 \|issue=24 \|pages=e223–e393 \|date=December 2022 \|pmid=36334952 \|pmc=9860464 \|doi=10.1016/j.jacc.2022.08.004 \|url=}}</ref> <ref name="url2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines \| JACC">{{cite web \|url=https://www.jacc.org/doi/10.1016/j.jacc.2022.08.004 \|title=2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines \| JACC \|format= \|work= \|accessdate=}}</ref>==

	=== Multidisciplinary Aortic Team and Shared Decision-Making<ref name="url2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines \| JACC" /> ===		=== Multidisciplinary Aortic Team and Shared Decision-Making<ref name="url2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines \| JACC" /> ===
Line 185:		Line 185:

	== '''References''' ==		== '''References''' ==
			<references />

Datopotamab deruxtecan-dlnk

2026-04-28T00:58:04Z

Show changes

Sandbox

2026-04-28T00:07:58Z

Multidisciplinary Aortic Team and Shared Decision-Making[2]

Show changes

Datopotamab deruxtecan-dlnk

2026-04-27T23:52:27Z

Sandbox

2026-04-27T23:15:44Z

Show changes

Atrial fibrillation

2026-04-27T21:51:47Z

Rhythm Control

Show changes

User:Hasnain Ali

2026-04-27T20:24:40Z

← Older revision		Revision as of 20:24, 27 April 2026
Line 10:		Line 10:
	I create original content on my areas of interest and refresh older chapters to keep the medical information current.		I create original content on my areas of interest and refresh older chapters to keep the medical information current.

	* Resident ~~Medical Officer with Dept. of Neurology~~, Liaquat University hospital Hyderabad/Jamshoro, Pakistan.		* Resident, Liaquat University hospital Hyderabad/Jamshoro, Pakistan.

	I provide inpatient and outpatient neurological care, managing up to 5 inpatients daily and around 30 clinic and emergency patients per week. Alongside clinical duties, I participated in multidisciplinary academic activities and contributed to research through systematic data collection and documentation.		I provide inpatient and outpatient neurological care, managing up to 5 inpatients daily and around 30 clinic and emergency patients per week. Alongside clinical duties, I participated in multidisciplinary academic activities and contributed to research through systematic data collection and documentation.

Industrial and organizational psychology

2026-04-27T20:07:19Z

Career calling

← Older revision		Revision as of 20:07, 27 April 2026
(4 intermediate revisions by the same user not shown)
Line 18:		Line 18:
	* [[Empowerment(psychology)\|Empowerment]]		* [[Empowerment(psychology)\|Empowerment]]
	* [[Engagement (psychology)\|Engagement]]		* [[Engagement (psychology)\|Engagement]]
			* [[Career calling]]
	* [[Job satisfaction]]		* [[Job satisfaction]]
	* [[Burnout (psychology)\|Burnout]]		* [[Burnout (psychology)\|Burnout]]
Line 63:		Line 64:
	* "Would you say you are thriving or struggling with the following types of bonds or relationships at work?"		* "Would you say you are thriving or struggling with the following types of bonds or relationships at work?"

	A separate body of research has emerged more recently that gives a broader definition to thriving, but does not cite the above research that has used factor analysis to identify core features~~<ref>~~<ref name="pmid28913621">{{cite journal\| author=Brady KJS, Trockel MT, Khan CT, Raj KS, Murphy ML, Bohman B et al.\| title=What Do We Mean by Physician Wellness? A Systematic Review of Its Definition and Measurement. \| journal=Acad Psychiatry \| = 2017 \| volume= \| issue= \| pages= \| pmid=28913621 \| doi=10.1007/s40596-017-0781-6 \| pmc= \| url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28913621 }} </ref><ref>Feeney, B. C., & Collins, N. L. (2015). A new look at social support: A theoretical perspective on thriving through relationships. Personality and Social Psychology Review, 19(2), 113-147. {{doi\|10.1177/1088868314544222}}</ref>.		A separate body of research has emerged more recently that gives a broader definition to thriving, but does not cite the above research that has used factor analysis to identify core features<ref name="pmid28913621">{{cite journal\| author=Brady KJS, Trockel MT, Khan CT, Raj KS, Murphy ML, Bohman B et al.\| title=What Do We Mean by Physician Wellness? A Systematic Review of Its Definition and Measurement. \| journal=Acad Psychiatry \| = 2017 \| volume= \| issue= \| pages= \| pmid=28913621 \| doi=10.1007/s40596-017-0781-6 \| pmc= \| url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28913621 }} </ref><ref>Feeney, B. C., & Collins, N. L. (2015). A new look at social support: A theoretical perspective on thriving through relationships. Personality and Social Psychology Review, 19(2), 113-147. {{doi\|10.1177/1088868314544222}}</ref>.

	==== Importance====		==== Importance====
Line 177:		Line 178:
	* Emotional: I feel energetic at my job; I am enthusiastic in my job		* Emotional: I feel energetic at my job; I am enthusiastic in my job
	* Cognitive: At work, I focus a great deal of attention on my job; At work, I am absorbed by my job		* Cognitive: At work, I focus a great deal of attention on my job; At work, I am absorbed by my job

			===Career calling ===
			Career calling has various definitions, a more recent definition by Rosso and Wrzesniewski is, "meaningful beckoning toward work activities that are morally, socially, and personally significant"<ref name="Rosso2010">{{cite journal \| last1=Rosso \| first1=Brent D. \| last2=Dekas \| first2=Kathryn H. \| last3=Wrzesniewski \| first3=Amy \| title=On the meaning of work: A theoretical integration and review \| journal=Research in Organizational Behavior \| volume=30 \| date=2010 \| doi=10.1016/j.riob.2010.09.001 \| pages=91–127 \| url=https://linkinghub.elsevier.com/retrieve/pii/S0191308510000067 \| access-date=2026-04-27}}</ref>. calling can be measured with<ref name="Dik2012">{{cite journal \| last1=Dik \| first1=Bryan J. \| last2=Eldridge \| first2=Brandy M. \| last3=Steger \| first3=Michael F. \| last4=Duffy \| first4=Ryan D. \| title=Development and Validation of the Calling and Vocation Questionnaire (CVQ) and Brief Calling Scale (BCS) \| journal=Journal of Career Assessment \| volume=20 \| issue=3 \| date=2012 \| issn=1069-0727 \| doi=10.1177/1069072711434410 \| pages=242–263 \| url=https://journals.sagepub.com/doi/10.1177/1069072711434410 \| access-date=2026-04-27}}</ref>:
			# I have a calling to my current line of work.
			# I have a good understanding of my calling as it applies to my career.

			Career calling can be promoted by a career calling climate at work<ref name="Chen 2025">{{cite journal \| last1=Chen \| first1=Jiatian \| last2=May \| first2=Douglas R. \| last3=Schwoerer \| first3=Catherine E. \| title=Career calling climate: The development and validation of a scale for a new construct \| journal=Journal of Management & Organization \| volume=31 \| issue=4 \| date=2025 \| issn=1833-3672 \| doi=10.1017/jmo.2023.16 \| pages=1688–1707 \| url=https://www.cambridge.org/core/product/identifier/S1833367223000160/type/journal_article \| access-date=2026-04-27}}</ref>.

			Calling may increase engagement at work, especially is organizational commitment is present<ref name="Cao2019">{{cite journal \| last1=Cao \| first1=Yudi \| last2=Liu \| first2=Jingying \| last3=Liu \| first3=Kejia \| last4=Yang \| first4=Mengyu \| last5=Liu \| first5=Yanhui \| title=The mediating role of organizational commitment between calling and work engagement of nurses: A cross-sectional study \| journal=International Journal of Nursing Sciences \| volume=6 \| issue=3 \| date=2019-07-10 \| issn=2352-0132 \| pmid=31508452 \| pmc=6722477 \| doi=10.1016/j.ijnss.2019.05.004 \| pages=309–314 \| url=https://pubmed.ncbi.nlm.nih.gov/31508452 \| access-date=2026-04-27}}</ref> as measured by the organizational commitment scale (OCS)<ref name="Allen2011">{{cite journal \| last1=Allen \| first1=Natalie J. \| last2=Meyer \| first2=John P. \| title=The measurement and antecedents of affective, continuance and normative commitment to the organization \| journal=Journal of Occupational Psychology \| volume=63 \| issue=1 \| date=1990 \| issn=0305-8107 \| doi=10.1111/j.2044-8325.1990.tb00506.x \| pages=1–18 \| url=https://bpspsychub.onlinelibrary.wiley.com/doi/10.1111/j.2044-8325.1990.tb00506.x \| access-date=2026-04-27}}</ref>.

	===Satisfaction===		===Satisfaction===

Atrial fibrillation overview

2026-04-27T17:15:33Z

Show changes

Supraventricular tachycardia

2026-04-27T17:08:57Z

Show changes

Chronic stable angina overview

2026-04-25T15:44:25Z

Treatment

Show changes

Cardiomyopathy overview

2026-04-25T14:08:19Z

← Older revision		Revision as of 14:08, 25 April 2026
(15 intermediate revisions by the same user not shown)
Line 1:		Line 1:
	__NOTOC__		__NOTOC__
	{{Cardiomyopathy}}		{{Cardiomyopathy}}
	{{CMG}}; {{AE}} {{EdzelCo}}		{{CMG}}; {{AE}} {{EdzelCo}} {{MSD}}

	==Overview==		==Overview==
Line 29:		Line 29:
	==Treatment==		==Treatment==
	===Medical Therapy===		===Medical Therapy===
	Treatment ~~depends~~ on the ~~type~~ of cardiomyopathy, ~~but may include medication~~, ~~implanted [[artificial pacemaker\|pacemakers]]~~, ~~[[Implantable cardioverter~~-~~defibrillator~~\|~~defribillators]]~~, ~~or [[ventricular assist device]]s (LVADs)~~, ~~or [[ablation]]~~. ~~The goal of treatment is often~~ symptom relief, and ~~some~~ patients ~~may eventually require a [[~~heart transplant]]. ~~Treatment~~ of ~~cardiomyopathy (~~and ~~other heart diseases) using alternative methods such as [[stem cell therapy]] is commercially available but is not supported by convincing evidence~~.		Treatment is phenotype-directed and includes guideline-directed medical therapy (GDMT) for heart failure syndromes and targeted therapy for specific cardiomyopathies such as hypertrophic cardiomyopathy (HCM). In HCM, management includes symptom-directed pharmacotherapy (beta-blocker or nondihydropyridine calcium-channel blocker, with disopyramide or a cardiac myosin inhibitor in selected adults with obstructive physiology), risk-based use of ICDs, and septal reduction therapy at experienced centers when symptoms persist despite medical therapy.<ref name="pmid38718139">{{cite journal \|vauthors=Ommen SR, Ho CY, Asif IM, Balaji S, Burke MA, Day SM, Dearani JA, Epps KC, Evanovich L, Ferrari VA, Joglar JA, Khan SS, Kim JJ, Kittleson MM, Krittanawong C, Martinez MW, Mital S, Naidu SS, Saberi S, Semsarian C, Times S, Waldman CB \|title=2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines \|journal=Circulation \|volume=149 \|issue=23 \|pages=e1239–e1311 \|date=June 2024 \|pmid=38718139 \|doi=10.1161/CIR.0000000000001250 \|url=}}</ref> <ref name="pmid35363499">{{cite journal \|vauthors=Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW \|title=2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines \|journal=Circulation \|volume=145 \|issue=18 \|pages=e895–e1032 \|date=May 2022 \|pmid=35363499 \|doi=10.1161/CIR.0000000000001063 \|url=}}</ref>For cardiomyopathy with HFrEF, foundational GDMT consists of an ARNI/ACE inhibitor/ARB, evidence-based beta-blocker, mineralocorticoid receptor antagonist, and SGLT2 inhibitor, with additional therapies and device-based treatment individualized by EF, QRS, symptoms, and comorbidities.<ref name="pmid35363499">{{cite journal \|vauthors=Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW \|title=2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines \|journal=Circulation \|volume=145 \|issue=18 \|pages=e895–e1032 \|date=May 2022 \|pmid=35363499 \|doi=10.1161/CIR.0000000000001063 \|url=}}</ref> Goals include symptom relief, prevention of sudden cardiac death (when relevant, e.g., HCM), and modification of heart-failure trajectory; patients with advanced heart failure despite GDMT should be referred to an advanced HF team for consideration of transplant and/or durable mechanical circulatory support.<ref name="pmid35363500">{{cite journal \|vauthors=Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW \|title=2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines \|journal=Circulation \|volume=145 \|issue=18 \|pages=e876–e894 \|date=May 2022 \|pmid=35363500 \|doi=10.1161/CIR.0000000000001062 \|url=}}</ref> In HCM with atrial fibrillation, oral anticoagulation is recommended irrespective of CHA₂DS₂-VASc, and rhythm and/or rate control should be individualized.<ref name="pmid38718139">{{cite journal \|vauthors=Ommen SR, Ho CY, Asif IM, Balaji S, Burke MA, Day SM, Dearani JA, Epps KC, Evanovich L, Ferrari VA, Joglar JA, Khan SS, Kim JJ, Kittleson MM, Krittanawong C, Martinez MW, Mital S, Naidu SS, Saberi S, Semsarian C, Times S, Waldman CB \|title=2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines \|journal=Circulation \|volume=149 \|issue=23 \|pages=e1239–e1311 \|date=June 2024 \|pmid=38718139 \|doi=10.1161/CIR.0000000000001250 \|url=}}</ref>

	===Surgery===		===Surgery===
	~~There~~ are ~~several types~~ of ~~surgery used~~ to ~~treat cardiomyopathy. They include~~ septal ablation, ~~[[septal myectomy]]~~, ~~surgically implanted devices to improve~~ the ~~function~~ of the ~~heart~~, ~~and [[heart transplant]]~~.		Procedural and surgical options are phenotype-specific and should be performed at experienced centers when indicated.<ref name="pmid38718139">{{cite journal \|vauthors=Ommen SR, Ho CY, Asif IM, Balaji S, Burke MA, Day SM, Dearani JA, Epps KC, Evanovich L, Ferrari VA, Joglar JA, Khan SS, Kim JJ, Kittleson MM, Krittanawong C, Martinez MW, Mital S, Naidu SS, Saberi S, Semsarian C, Times S, Waldman CB \|title=2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines \|journal=Circulation \|volume=149 \|issue=23 \|pages=e1239–e1311 \|date=June 2024 \|pmid=38718139 \|doi=10.1161/CIR.0000000000001250 \|url=}}</ref> For symptomatic obstructive HCM refractory to medical therapy, septal reduction therapy includes surgical septal myectomy or (in selected patients) alcohol septal ablation. Advanced heart failure may require durable mechanical circulatory support and/or heart transplantation after evaluation by an advanced HF team.<ref name="pmid38718139">{{cite journal \|vauthors=Ommen SR, Ho CY, Asif IM, Balaji S, Burke MA, Day SM, Dearani JA, Epps KC, Evanovich L, Ferrari VA, Joglar JA, Khan SS, Kim JJ, Kittleson MM, Krittanawong C, Martinez MW, Mital S, Naidu SS, Saberi S, Semsarian C, Times S, Waldman CB \|title=2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines \|journal=Circulation \|volume=149 \|issue=23 \|pages=e1239–e1311 \|date=June 2024 \|pmid=38718139 \|doi=10.1161/CIR.0000000000001250 \|url=}}</ref><ref name="pmid35363500">{{cite journal \|vauthors=Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW \|title=2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines \|journal=Circulation \|volume=145 \|issue=18 \|pages=e876–e894 \|date=May 2022 \|pmid=35363500 \|doi=10.1161/CIR.0000000000001062 \|url=}}</ref>

	===Primary Prevention===		===Primary Prevention===
	~~Methods of primary~~ prevention ~~for cardiomyopathy include; maintaining a healthy weight~~, ~~not smoking~~, ~~avoiding~~ alcohol and illicit drugs, ~~reducing stress~~, and ~~treating underlying conditions such as [[diabetes]] and [[high blood pressure]]~~.		Primary prevention focuses on ‘at risk’ (Stage A) and ‘pre-HF’ (Stage B) management: control hypertension, diabetes, obesity, and other cardiovascular risk factors; avoid cardiotoxins (including excess alcohol and illicit drugs); and treat structural heart disease early to prevent progression to symptomatic HF.<ref name="pmid35363500">{{cite journal \|vauthors=Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW \|title=2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines \|journal=Circulation \|volume=145 \|issue=18 \|pages=e876–e894 \|date=May 2022 \|pmid=35363500 \|doi=10.1161/CIR.0000000000001062 \|url=}}</ref><ref name="pmid38033089">{{cite journal \|vauthors=Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, Deswal A, Eckhardt LL, Goldberger ZD, Gopinathannair R, Gorenek B, Hess PL, Hlatky M, Hogan G, Ibeh C, Indik JH, Kido K, Kusumoto F, Link MS, Linta KT, Marcus GM, McCarthy PM, Patel N, Patton KK, Perez MV, Piccini JP, Russo AM, Sanders P, Streur MM, Thomas KL, Times S, Tisdale JE, Valente AM, Van Wagoner DR \|title=2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines \|journal=Circulation \|volume=149 \|issue=1 \|pages=e1–e156 \|date=January 2024 \|pmid=38033089 \|pmc=11095842 \|doi=10.1161/CIR.0000000000001193 \|url=}}</ref>

	==Preferences==		==Preferences==

Datopotamab deruxtecan-dlnk

2026-04-25T05:40:10Z

Show changes

Datopotamab deruxtecan-dlnk

2026-04-25T03:20:50Z

Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |genericName=DATROWAY |aOrAn=a |drugClass=Trop-2-directed antibody and topoisomerase inhibitor conjugate |indicationType=treatment |indication=DATROWAY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of: 1. Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) DATROWAY is indicated for the treatment of adult patients with locally advanced or metastati..."

Show changes

Hypertension

2026-04-23T14:37:46Z

Modified the treatment section in line with the 2025 AHA/ACC guidelines for the management of hypertension

← Older revision		Revision as of 14:37, 23 April 2026
(2 intermediate revisions by the same user not shown)
Line 1:		Line 1:
	__NOTOC__		__NOTOC__
	{{SI}}		{{SI}}
	{{CMG}}; {{AE}} {{Sara.Zand}} {{USAMA}}		{{CMG}}; {{AE}} {{Sara.Zand}} {{USAMA}} {{HMA}}

	{{SK}} Blood pressure; hypertension; high blood pressure; systolic blood pressure; essential hypertension		{{SK}} Blood pressure; hypertension; high blood pressure; systolic blood pressure; essential hypertension
Line 858:		Line 858:
	:*[[Renin-angiotensin-convertng enzyme inhibitors]] ([[ACEI]] or [[ARB]])		:*[[Renin-angiotensin-convertng enzyme inhibitors]] ([[ACEI]] or [[ARB]])
	:*[[Thiazide-like diuretic]]		:*[[Thiazide-like diuretic]]
	::*~~[[Betablocker]] is~~ first line ~~therapy in the presence of~~ [[~~angina~~]] ~~and [[~~heart failure]].		::*Beta-blockers are not first-line for hypertension unless specific comorbidities (e.g., [[coronary heart disease]], heart failure with reduced ejection fraction) are present.
	::*Second-line lowering [[BP]] agents are used in resistant [[hypertension]] or specific conditions.		::*Second-line lowering [[BP]] agents are used in resistant [[hypertension]] or specific conditions

			* For Stage 2 hypertension (BP ≥140/90 mm Hg), initiation of antihypertensive therapy with two first-line agents of different classes, ideally in a single-pill combination, is recommended to improve blood pressure control and medication adherence.

	*The mainstay of therapy for [[resistant hypertension]] is:		*The mainstay of therapy for [[resistant hypertension]] is:
Line 865:		Line 867:
	:*Improving medications adherence		:*Improving medications adherence
	:*Diagnosis and treatment of the causes of [[secondary hypertension]]		:*Diagnosis and treatment of the causes of [[secondary hypertension]]
	:*Adding [[spironolactone]] or [[hydralazine]] or [[ minoxidil]] to first line therapy ([[CCB]]s, [[inhibitors of RAS]], [[chlorthalidone]].		:*Adding [[spironolactone]] or [[hydralazine]] or [[ minoxidil]] to first line therapy ([[CCB]]s, [[inhibitors of RAS]], [[chlorthalidone]]).
			:*Renal Denervation may be reasonable as an adjunct in select patients

	{{familytree/start}}		{{familytree/start}}
Line 874:		Line 877:
	{{familytree \| B01 \| \| \| B02 \| \| \| \| \| B03 \| \| \| \|B04\| \|B01=Nomal [[BP]] ([[BP]]<120/80 mmHg)\|B02=Elevated [[BP]] ([[BP]]120-129/<80mmHg)\|B03=Stage1 [[hypertension]](BP 130-139/80-89mmHg\|B04=Stage 2 [[hypertension]] ([[BP]]≥ 140/90}}		{{familytree \| B01 \| \| \| B02 \| \| \| \| \| B03 \| \| \| \|B04\| \|B01=Nomal [[BP]] ([[BP]]<120/80 mmHg)\|B02=Elevated [[BP]] ([[BP]]120-129/<80mmHg)\|B03=Stage1 [[hypertension]](BP 130-139/80-89mmHg\|B04=Stage 2 [[hypertension]] ([[BP]]≥ 140/90}}
	{{familytree \| \|!\| \| \| \| \|!\| \| \| \| \| \| \|!\| \| \| \| \|!\| }}		{{familytree \| \|!\| \| \| \| \|!\| \| \| \| \| \| \|!\| \| \| \| \|!\| }}
	{{familytree \| C01 \| \| \| C02 \| \| \| \| \| C03 \| \| \| \|C04\| \|C01=Life style modifications\|C02=Nonpharmocological therapy (class1)\|C03= 10 ~~years~~ cardiovascular disease ([[CVD]]) ~~risk≥ 10~~%\|C04=Non pharmacological therapy and [[BP]]lowering medication}}		{{familytree \| C01 \| \| \| C02 \| \| \| \| \| C03 \| \| \| \|C04\| \|C01=Life style modifications\|C02=Nonpharmocological therapy (class1)\|C03= 10-year cardiovascular disease (CVD) risk ≥7.5% by PREVENT\|C04=Non pharmacological therapy and [[BP]]lowering medication}}
	{{familytree \| \|!\| \| \| \| \|!\| \| \| \| \|,\|-\|^\|-\|.\| \| \|!\| \| \| \| \| \| \| \| \|}}		{{familytree \| \|!\| \| \| \| \|!\| \| \| \| \|,\|-\|^\|-\|.\| \| \|!\| \| \| \| \| \| \| \| \|}}
	{{familytree \| \|D01\| \| \| D02 \| \| \| D03 \| \| D04 \|!\| \| \| \| \| \| \| D01=Reevaulation in 1 year (class 2a)\|D02=Reevaulation in 3-6 months (class 1)\|D03= NO, nonpharmocological therapy (class1)\|D04= Yes,non pharmacological therapy and [[BP]] lowering medication}}		{{familytree \| \|D01\| \| \| D02 \| \| \| D03 \| \| D04 \|!\| \| \| \| \| \| \| D01=Reevaulation in 1 year (class 2a)\|D02=Reevaulation in 3-6 months (class 1)\|D03= NO, nonpharmocological therapy (class1)\|D04= Yes,non pharmacological therapy and [[BP]] lowering medication}}
Line 1,217:		Line 1,220:

	*[[Surgery\|Surgical]] procedure may be performed for patients with [[secondary hypertension]] such as [[coarctation of aorta]], [[Primary aldosteronism\|primary aldosteronism.]]		*[[Surgery\|Surgical]] procedure may be performed for patients with [[secondary hypertension]] such as [[coarctation of aorta]], [[Primary aldosteronism\|primary aldosteronism.]]
			*Renal Denervation may be reasonable as an adjunct in select patients with resistant hypertension or drug intolerance, but requires evaluation by a multidisciplinary team.

	===Prevention===		===Prevention===
Line 1,222:		Line 1,226:
	*Effective measures for the [[primary prevention]] of hypertension include: <ref name="WheltonCarey2018">{{cite journal\|last1=Whelton\|first1=Paul K.\|last2=Carey\|first2=Robert M.\|last3=Aronow\|first3=Wilbert S.\|last4=Casey\|first4=Donald E.\|last5=Collins\|first5=Karen J.\|last6=Dennison Himmelfarb\|first6=Cheryl\|last7=DePalma\|first7=Sondra M.\|last8=Gidding\|first8=Samuel\|last9=Jamerson\|first9=Kenneth A.\|last10=Jones\|first10=Daniel W.\|last11=MacLaughlin\|first11=Eric J.\|last12=Muntner\|first12=Paul\|last13=Ovbiagele\|first13=Bruce\|last14=Smith\|first14=Sidney C.\|last15=Spencer\|first15=Crystal C.\|last16=Stafford\|first16=Randall S.\|last17=Taler\|first17=Sandra J.\|last18=Thomas\|first18=Randal J.\|last19=Williams\|first19=Kim A.\|last20=Williamson\|first20=Jeff D.\|last21=Wright\|first21=Jackson T.\|title=2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines\|journal=Hypertension\|volume=71\|issue=6\|year=2018\|issn=0194-911X\|doi=10.1161/HYP.0000000000000065}}</ref>		*Effective measures for the [[primary prevention]] of hypertension include: <ref name="WheltonCarey2018">{{cite journal\|last1=Whelton\|first1=Paul K.\|last2=Carey\|first2=Robert M.\|last3=Aronow\|first3=Wilbert S.\|last4=Casey\|first4=Donald E.\|last5=Collins\|first5=Karen J.\|last6=Dennison Himmelfarb\|first6=Cheryl\|last7=DePalma\|first7=Sondra M.\|last8=Gidding\|first8=Samuel\|last9=Jamerson\|first9=Kenneth A.\|last10=Jones\|first10=Daniel W.\|last11=MacLaughlin\|first11=Eric J.\|last12=Muntner\|first12=Paul\|last13=Ovbiagele\|first13=Bruce\|last14=Smith\|first14=Sidney C.\|last15=Spencer\|first15=Crystal C.\|last16=Stafford\|first16=Randall S.\|last17=Taler\|first17=Sandra J.\|last18=Thomas\|first18=Randal J.\|last19=Williams\|first19=Kim A.\|last20=Williamson\|first20=Jeff D.\|last21=Wright\|first21=Jackson T.\|title=2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines\|journal=Hypertension\|volume=71\|issue=6\|year=2018\|issn=0194-911X\|doi=10.1161/HYP.0000000000000065}}</ref>

	:*[[Weight loss]]: ~~Reduction 1 mmHg~~ in ~~[[blood pressure]] for every one kilogram [[~~weight reduction]]		:*Weight loss: Sustained ≥5% reduction in body weight or ≥3 kg/m² reduction in BMI. Expect ~1 mmHg SBP drop per 1 kg lost
	:*[[Healthy diet]]: A [[diet]] rich in [[fruits]], [[vegetables]], [[whole grains]], [[low-fat dairy products]], reduced content of saturated and [[total fat]]		:*[[Healthy diet]]: A [[diet]] rich in [[fruits]], [[vegetables]], [[whole grains]], [[low-fat dairy products]], reduced content of saturated and [[total fat]]
	:*[[Reduced]] intake of dietary [[sodium]]: ~~Less than 1000-15000~~ mg/day		:*Reduced intake of dietary sodium: Target <2300 mg/day, with ideal limit <1500 mg/day
	:*Enhanced intake of [[dietary~~]][[~~ potassium]]:3500–5000 mg/d by intaking rich diet with [[~~potassium~~]]		:*Enhanced intake of dietary potassium: 3500–5000 mg/d by ideally intaking rich diet with potassium, or moderate supplementation (<80 mmol/day)
			:*Use of salt substitutes: Replace regular table/cooking salt with potassium-based salt substitutes. Avoid in [[CKD]] or with potassium-sparing drugs
			:*Reduced alcohol intake: Abstinence is optimal for BP control. If consumed, reduce intake by >50% to ≤1 drink/day for women or ≤2 drinks/day for men
	:*[[Physical activity]]: [[Aerobic]] ( 90–150 min/week), dynamic resistance (90–150 min/week), [[Isometric exercise\|Isometric]] resistance (4 × 2 min handgrip, 1 min rest between exercises, 3 sessions per week)		:*[[Physical activity]]: [[Aerobic]] ( 90–150 min/week), dynamic resistance (90–150 min/week), [[Isometric exercise\|Isometric]] resistance (4 × 2 min handgrip, 1 min rest between exercises, 3 sessions per week)
	:*~~Reduced [[alcohol]] intake~~: ~~Men ≤2 drinks daily, Women ≤1 drink daily~~		:*Stress reduction: Transcendental meditation (2 × 20 min/day) or device-guided slow breathing (<10 breaths/min for 15 min/day) may be reasonable adjuncts to lifestyle modification

	*Once diagnosed and treated, patients with hypertension are followed-up every month for evaluation of medication adherence and response to treatment.		*Once diagnosed and treated, patients with hypertension are followed-up every month for evaluation of medication adherence and response to treatment.

			=== Treatment Goal ===
			For all adults with confirmed hypertension, the recommended target is <130/80 mm Hg. For high-risk patients (10-year CVD risk ≥7.5% by PREVENT), achieving SBP <120 mm Hg is encouraged to reduce major adverse events.

	==References==		==References==

Sandbox

2026-04-23T00:19:19Z

Medical Treatment of Patients With Thoracic Aortic Disease

← Older revision		Revision as of 00:19, 23 April 2026
(2 intermediate revisions by the same user not shown)
Line 35:		Line 35:
	{\| class="wikitable"		{\| class="wikitable"
	\|-		\|-
	\|[[ACC AHA guidelines classification scheme#Classification of Recommendations\|Class I]]		\|colspan="1" style="text-align:center; background:LightGreen"\|[[ACC AHA guidelines classification scheme#Classification of Recommendations\|Class I]]
	\|-		\|-
	\|"'''1.''' Stringent control of ~~<nowiki>~~[[hypertension]]~~</nowiki>~~, ~~<nowiki>~~[[lipid profile]]~~</nowiki>~~ optimization, <nowiki>[[smoking cessation]]</nowiki>, and other <nowiki>[[atherosclerosis]]</nowiki> risk-reduction measures should be instituted for all patients with <nowiki>[[thoracic aortic aneurysm]]</nowiki> not requiring immediate surgical intervention, as well as for patients who are not considered surgical or stent graft candidates. ''([[ACC AHA guidelines classification scheme#Level of Evidence\|Level of Evidence: C]])''"		\|colspan="1" style="text-align:center; background:LightGreen"\|'''1.''' Stringent control of [[hypertension]], [[lipid profile]] optimization, <nowiki>[[smoking cessation]]</nowiki>, and other <nowiki>[[atherosclerosis]]</nowiki> risk-reduction measures should be instituted for all patients with <nowiki>[[thoracic aortic aneurysm]]</nowiki> not requiring immediate surgical intervention, as well as for patients who are not considered surgical or stent graft candidates. ''([[ACC AHA guidelines classification scheme#Level of Evidence\|Level of Evidence: C]])''"
	\|}		\|}

← Older revision		Revision as of 23:52, 27 April 2026
Line 45:		Line 45:
	DATROWAY can cause severe, life-threatening, or fatal interstitial lung disease (ILD) or pneumonitis.		DATROWAY can cause severe, life-threatening, or fatal interstitial lung disease (ILD) or pneumonitis.

	Locally Advanced or Metastatic NSCLC		'''Locally Advanced or Metastatic NSCLC''

	In the pooled safety population of 484 patients with NSCLC from TROPION-Lung01, TROPION-Lung05, and TROPION-PanTumor01 ~~[see Adverse Reactions (6.1)]~~, ILD/pneumonitis occurred in 7% of patients treated with DATROWAY, including 0.6% of patients with Grade 3 and 0.4% with Grade 4. There were 8 (1.7%) fatal cases. The median time to onset for ILD was 1.4 months (range: 0.2 months to 9 months). Eleven patients (2.3%) had DATROWAY withheld and 20 patients (4.1%) permanently discontinued DATROWAY due to ILD/pneumonitis. Systemic corticosteroids were required in 79% (26/33) of patients with ILD/pneumonitis. ILD/pneumonitis resolved in 45% of patients.		In the pooled safety population of 484 patients with NSCLC from TROPION-Lung01, TROPION-Lung05, and TROPION-PanTumor01, ILD/pneumonitis occurred in 7% of patients treated with DATROWAY, including 0.6% of patients with Grade 3 and 0.4% with Grade 4. There were 8 (1.7%) fatal cases. The median time to onset for ILD was 1.4 months (range: 0.2 months to 9 months). Eleven patients (2.3%) had DATROWAY withheld and 20 patients (4.1%) permanently discontinued DATROWAY due to ILD/pneumonitis. Systemic corticosteroids were required in 79% (26/33) of patients with ILD/pneumonitis. ILD/pneumonitis resolved in 45% of patients.

	Unresectable or Metastatic Breast Cancer		Unresectable or Metastatic Breast Cancer
Line 86:		Line 86:


	The safety of DATROWAY was evaluated in 125 patients with EGFR-mutated NSCLC who received DATROWAY 6 mg/kg administered as an intravenous infusion once every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity in TROPION-Lung05 and TROPION-Lung01 ~~[see Clinical Studies (14.1)]~~ as well as TROPION-PanTumor01 (NCT03401385). Among these patients, the median duration of treatment was 6.1 months (range 0.7 months to 41.7 months).		The safety of DATROWAY was evaluated in 125 patients with EGFR-mutated NSCLC who received DATROWAY 6 mg/kg administered as an intravenous infusion once every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity in TROPION-Lung05 and TROPION-Lung01 as well as TROPION-PanTumor01 (NCT03401385). Among these patients, the median duration of treatment was 6.1 months (range 0.7 months to 41.7 months).

	The median age was 63 years (range: 36 to 81), 56% of patients were <65 years, 62% of patients were female; 66% were Asian, 26% were White, 0.8% were Black, 6% were other races; and 2.4% were of Hispanic ethnicity.		The median age was 63 years (range: 36 to 81), 56% of patients were <65 years, 62% of patients were female; 66% were Asian, 26% were White, 0.8% were Black, 6% were other races; and 2.4% were of Hispanic ethnicity.
Line 161:		Line 161:

	Reconstitute immediately before dilution.		Reconstitute immediately before dilution.
	More than one vial may be needed for a full dose. Calculate the dose (mg), the total volume of reconstituted DATROWAY solution required, and the number of vial(s) of DATROWAY needed ~~[see Dosage and Administration (2.2)]~~.		More than one vial may be needed for a full dose. Calculate the dose (mg), the total volume of reconstituted DATROWAY solution required, and the number of vial(s) of DATROWAY needed.
	Reconstitute each 100 mg vial using a sterile syringe to slowly inject 5 mL of Sterile Water for Injection into each vial to obtain a final concentration of 20 mg/mL.		Reconstitute each 100 mg vial using a sterile syringe to slowly inject 5 mL of Sterile Water for Injection into each vial to obtain a final concentration of 20 mg/mL.
	Swirl the vial gently until completely dissolved. Do not shake.		Swirl the vial gently until completely dissolved. Do not shake.
Line 286:		Line 286:
	Interstitial Lung Disease/Pneumonitis		Interstitial Lung Disease/Pneumonitis

	Inform patients of the risks of severe or fatal ILD. Advise patients to contact their healthcare provider immediately for any of the following: cough, shortness of breath, fever, or other new or worsening respiratory symptoms ~~[see Warnings and Precautions (5.1)]~~.		Inform patients of the risks of severe or fatal ILD. Advise patients to contact their healthcare provider immediately for any of the following: cough, shortness of breath, fever, or other new or worsening respiratory symptoms.
	Ocular Adverse Reactions		Ocular Adverse Reactions

	Inform patients about the need for eye exams at initiation and during treatment with DATROWAY ~~[see Dosage and Administration (2.3)]~~.		Inform patients about the need for eye exams at initiation and during treatment with DATROWAY .
	Advise patients to contact their healthcare provider if they experience any eye symptoms.		Advise patients to contact their healthcare provider if they experience any eye symptoms.
	Advise patients to use preservative-free lubricating eye drops several times daily and to avoid use of contact lenses during treatment with DATROWAY.		Advise patients to use preservative-free lubricating eye drops several times daily and to avoid use of contact lenses during treatment with DATROWAY.